A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
about
BiP-mediated closing of the Sec61 channel limits Ca2+ leakage from the ERReduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sitesA gain-of-function mutation in adenylate cyclase 3 protects mice from diet-induced obesityERAD and protein import defects in a sec61 mutant lacking ER-lumenal loop 7.Heterozygous Loss-of-Function SEC61A1 Mutations Cause Autosomal-Dominant Tubulo-Interstitial and Glomerulocystic Kidney Disease with AnemiaEndoplasmic reticulum stress and oxidative stress in cell fate decision and human disease.Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease.Contribution of Sec61α to the life cycle of Ebola virus.Proteasome 19S RP binding to the Sec61 channel plays a key role in ERAD.Protection of Human Pancreatic Islets from Lipotoxicity by Modulation of the TransloconEndoplasmic reticulum stress in liver disease.Luminal Ca2+ depletion during the unfolded protein response in Xenopus oocytes: cause and consequence.Random mutagenesis of the mouse genome: a strategy for discovering gene function and the molecular basis of disease.Targeting endoplasmic reticulum stress in metabolic disease.The role of the unfolded protein response in diabetes mellitus.Protein transport into the human ER and related diseases, Sec61-channelopathies.Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.Plasma cell deficiency in human subjects with heterozygous mutations in Sec61 translocon alpha 1 subunit (SEC61A1).Co-chaperone Specificity in Gating of the Polypeptide Conducting Channel in the Membrane of the Human Endoplasmic Reticulum.Defective ER associated degradation of a model luminal substrate in yeast carrying a mutation in the 4th ER luminal loop of Sec61p.An Update on Sec61 Channel Functions, Mechanisms, and Related Diseases.Chaperone-Mediated Sec61 Channel Gating during ER Import of Small Precursor Proteins Overcomes Sec61 Inhibitor-Reinforced Energy Barrier.
P2860
Q24293288-7FEFC88F-91AA-4E2C-B8E4-C5D2EF526E44Q24318609-2C67F127-FA6A-4F1C-B8C5-C08DA0770FA1Q27335317-3099B97A-FB8F-48C5-B316-A8E1A280F59CQ27931054-1D834833-88B7-4BD8-A284-2F81E706EF90Q28118506-8EA9DDD2-644E-4708-B21C-0CD931FB5AD8Q33828303-905E57F6-48D0-4EE0-A476-24E71CDF164FQ33945101-2BFF0D78-D4CD-4478-B558-ADB6AEBFCC1FQ35299870-3E815487-8DFE-4B7E-A150-A80E8F0B0E79Q35556723-CF7B802D-4DAB-4932-AC9C-6E727211538BQ35919336-B4545174-8B4A-4DFD-A0D4-6A6376730537Q36031838-00EF0BA6-E9B2-4DC5-B9AA-D1ADBEC9E0AAQ36675399-F1E7754D-703C-4304-83F7-BD3E5B4CEAF3Q37174167-58C3DC8E-7302-471F-8F3F-2A23C459ECFCQ38074493-46D0F8EB-A77A-4A02-B1AF-395E4676007DQ38093057-F7643F3B-7C26-413B-8ACB-BF6660CA0328Q38220635-5FC2657A-F25E-49C5-A6D6-F9B2131490F8Q38307548-E7468BE3-96F5-4D49-8859-B50EE30DC7E0Q40104307-3D0B8607-2E1A-433A-ACB7-C926DA8FEDB1Q40289318-D1FE0D09-B623-4880-AAAE-468B676568B6Q41468188-34428CA5-B9EB-4DCE-AC97-32A2E42160A5Q47096501-A1454550-9953-48C7-B112-01FD44A322D0Q54964955-A5C16916-9413-46A6-BCE5-EFC81616B840
P2860
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@ast
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@en
type
label
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@ast
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@en
prefLabel
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@ast
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@en
P2860
P356
P1433
P1476
A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice.
@en
P2093
Matthew C Wheeler
Nicholas Gekakis
P2860
P304
P356
10.2337/DB08-1362
P407
P577
2009-11-23T00:00:00Z